Physiomics inks contract extension with Numab Therapeutics

(Sharecast News) – Mathematical modelling company Physiomics, which specialises in the development of oncology drugs and personalised medicine, confirmed a renewed contract with Numab Therapeutics on Tuesday.
The AIM-traded firm said the collaboration would revolve around PKPD modelling, assisting Numab’s ongoing clinical programs.

It said the new agreement extended the relationship between the two firms, as Physiomics previously undertook similar work for Numab on the same medical asset.

The project was set to continue for the next two years of the clinical programme, the board confirmed.

“We are delighted that we have a further opportunity to support Numab with its exciting clinical pipeline and look forward to working once again with their talented team,” said chief executive officer Dr Jim Millen.

 
 

At 1513 BST, shares in Physiomics were down 2.05% at 0.955p.

Reporting by Josh White for Sharecast.com.

Related Articles

Sign up to the Wealth DFM Newsletter

Please enable JavaScript in your browser to complete this form.
Name

Trending Articles

IFA Talk logo

IFA Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.

IFA Talk Podcast – listen to the latest episode